The Composition of Reconstituted High-Density Lipoproteins (rHDL) Dictates the Degree of rHDL Cargo- and Size-Remodeling via Direct Interactions with Endogenous Lipoproteins
- 5 September 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 30 (10) , 2634-2646
Abstract
The application of reconstituted high-density lipoproteins (rHDL) as a drug-carrier has during the last decade been established as a promising approach for effective receptor-mediated drug delivery, and its ability to target tumours has recently been confirmed in a clinical trial. The rHDL mimics the endogenous HDL, which is known to be highly dynamic and undergo extensive enzyme-mediated remodulations. Hence, to reveal the physiological rHDL stability, a thorough characterization of the dynamics of rHDL in biological relevant environments is needed. We employ a size-exclusion chromatography (SEC) method to evaluate the dynamics of discoidal rHDL in fetal bovine serum (FBS), where we track both the rHDL lipids (by the fluorescence from lipid-conjugated fluorophores) and apoA-I (by human apoA-I ELISA). We show by using lipoprotein depleted FBS and isolated lipoproteins that rHDL lipids can be transferred to endogenous lipoproteins via direct interactions in a non-enzymatic process, resulting in rHDL compositional- and size-remodeling. This type of dynamics could lead to misinterpretations of fluorescence-based rHDL uptake studies due to desorption of labile lipophilic fluorophores or off-target side-effects due to desorption of incorporated drugs. Importantly, we show how the degree of rHDL remodeling can be controlled by the compositional design of the rHDL. Understanding the correlation between the molecular properties of the rHDL constituents and their collective dynamics is essential for improving the rHDL-based drug delivery platform. Taken together, our work highlights the need to carefully consider the compositional design of rHDL and test its stability in a biological relevant environment, when developing rHDL for drug delivery purposes.Keywords
Funding Information
- Novo Nordisk Fonden (NNF17OC0028262)
- Lundbeck Foundation (R155-2013-14113)
This publication has 64 references indexed in Scilit:
- The effect of using binary mixtures of zwitterionic and charged lipids on nanodisc formation and stabilitySoft Matter, 2013
- A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterolJournal of Lipid Research, 2011
- Fluid phase lipid areas and bilayer thicknesses of commonly used phosphatidylcholines as a function of temperatureBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Activation of LDL Receptor Expression by Small RNAs Complementary to a Noncoding Transcript that Overlaps the LDLR PromoterChemistry & Biology, 2010
- A gel-based method for purification of apolipoprotein A-I from small volumes of plasmaJournal of Lipid Research, 2010
- 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E‐null miceThe FASEB Journal, 2010
- Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacyAdvanced Drug Delivery Reviews, 2009
- Templated Spherical High Density Lipoprotein NanoparticlesJournal of the American Chemical Society, 2009
- Efficient Coupling of Transducin to Monomeric Rhodopsin in a Phospholipid BilayerJournal of Biological Chemistry, 2008
- Characterization of human apolipoprotein A-I expressed in Escherichia coliBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1997